Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 4
1965 26
1966 46
1967 56
1968 44
1969 51
1970 58
1971 45
1972 60
1973 70
1974 77
1975 85
1976 120
1977 132
1978 172
1979 146
1980 206
1981 174
1982 206
1983 190
1984 249
1985 285
1986 280
1987 259
1988 275
1989 327
1990 366
1991 314
1992 350
1993 371
1994 475
1995 467
1996 588
1997 541
1998 589
1999 608
2000 733
2001 801
2002 783
2003 917
2004 985
2005 1240
2006 1344
2007 1383
2008 1538
2009 1634
2010 1847
2011 2038
2012 2129
2013 2177
2014 2280
2015 2431
2016 2431
2017 2415
2018 2431
2019 1120
2020 23
Text availability
Article attribute
Article type
Publication date

Search Results

37,348 results
Results by year
Filters applied: . Clear all
Page 1
Breast cancer: current developments in molecular approaches to diagnosis and treatment.
de la Mare JA, et al. Recent Pat Anticancer Drug Discov 2014 - Review. PMID 24171821
Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. ...
Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative br
Immune targeting in breast cancer.
Cimino-Mathews A, et al. Oncology (Williston Park) 2015 - Review. PMID 25979549 Free article.
The immune system is active in breast cancer, playing a dual role in tumor progression and in immune surveillance. Infiltrating immune cells are both prognostic and predictive of response to standard breast cancer therapies. ...Interest in breast cancer immunotherapy has been reignited by recent reports of objective responses in metastatic triple-negative breast cancer with both pembrolizumab (a programmed cell death protein 1 [PD-1] antagonist) and MPDL3280A (a programmed cell death ligand 1 [PD-L1] antagonist). ...
The immune system is active in breast cancer, playing a dual role in tumor progression and in immune surveillance. Infiltrating immun …
Precision medicine for metastatic breast cancer--limitations and solutions.
Arnedos M, et al. Nat Rev Clin Oncol 2015 - Review. PMID 26196250
The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientific and logistical challenges hinder its implementation in the clinic. ...The occurrence of secondary resistance, such as ESR1 mutations, following endocrine therapy poses a further challenge. Ultra-deep sequencing and monitoring of circulating tumour DNA (ctDNA) could permit early detection of the genetic events underlying resistance and inform on combination therapy approaches. ...
The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientif …
Adjuvant Endocrine Therapy.
Shah R and O'Regan RM. Cancer Treat Res 2018 - Review. PMID 29349755
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. ...Molecular profiling has allowed therapy to be tailored for an individual patient to some extent. However, further molecular studies are needed to individualize the choice and length of adjuvant hormone therapy. ...
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-p …
Chemotherapy for breast cancer (Review).
Hassan MS, et al. Oncol Rep 2010 - Review. PMID 20878101
The improvement in the understanding of the molecular biological basis of breast cancer provides possible targets for novel therapies. Personalised therapies for breast cancer based on the molecular characteristics of the tumour could improve the risk: benefit ratio of current therapies. ...
The improvement in the understanding of the molecular biological basis of breast cancer provides possible targets for novel therapies …
Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer.
Flaum LE and Gradishar WJ. Cancer Treat Res 2018 - Review. PMID 29349762
Endocrine therapy is the preferred first-line therapy for patients with advanced estrogen receptor (ER) positive, HER2-negative breast cancer who do not have symptomatic visceral disease. ...This review will summarize the existing literature regarding endocrine therapy in postmenopausal metastatic breast cancer and outline treatment approaches in the first-line metastatic setting and beyond....
Endocrine therapy is the preferred first-line therapy for patients with advanced estrogen receptor (ER) positive, HER2-negativ …
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Budd GT, et al. J Clin Oncol 2015 - Clinical Trial. PMID 25422488 Free PMC article.
PURPOSE: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. PATIENTS AND METHODS: A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with node-positive or high-risk node-negative early-stage breast cancer. ...
PURPOSE: To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage …
Advances in chemical pharmacotherapy to manage advanced breast cancer.
Gombos A and Awada A. Expert Opin Pharmacother 2017 - Review. PMID 27927046
Advanced breast cancer is still incurable. However, patients diagnosed with this fatal disease live longer. The selection of systemic therapy is mainly based on molecular subtype. ...Luminal breast cancer is also a field of active clinical research. So far triple negative breast cancer remains the subtype with the worse prognosis, even though new discoveries have been made to better understand the huge heterogeneity of this type of breast cancer. ...
Advanced breast cancer is still incurable. However, patients diagnosed with this fatal disease live longer. The selection of systemic …
Emilia: use cunning to survive cancer
Gligorov J, et al. Chin Clin Oncol 2018. PMID 29307196 Free article.
An update on treatment for post-menopausal metastatic breast cancer in elderly patients.
Menjak IB, et al. Expert Opin Pharmacother 2018 - Review. PMID 29601247
INTRODUCTION: Elderly patients make up a significant proportion of patients with metastatic breast cancer. With several options available in the metastatic setting for hormone positive breast cancer, these patients require an individualized approach to decision-making that considers multiple factors beyond performance status and chronologic age. ...The authors describe the role of comprehensive geriatric assessment (CGA) and highlight the considerations for the use of bone modifying agents, and HER2-targeted therapy for hormone positive/HER2+ patients. ...
INTRODUCTION: Elderly patients make up a significant proportion of patients with metastatic breast cancer. With several options avail …
37,348 results
Jump to page
Feedback